Metabolic Syndrome Evolution and Cardio-Kidney-Metabolic Multimorbidity: Implications for Targeted Prevention
Authors' conclusion
Both current MetS and a history of metabolic disorder, even in the absence of current MetS, may increase the risk of multimorbidity. Prevention targeting the LE8 may help reduce the risk and provide new perspectives for early intervention.
Study context
- Population
- Participants of the Kailuan study (2006–2010)participants included, 930 developed a multimorbidity
- Participants
- 36,201 participants
- Exposure
- Metabolic syndrome (MetS) evolution vs sustained metabolic health
- Outcome
- Incident cardio-kidney-metabolic multimorbidity
- Follow-up
- Median 12.02 years
Main finding
As reported in the abstract
Each group vs sustained metabolic health groupHazard ratio (95% CI)
Persistent metabolic disorder group
2.95(2.41–3.60)
MetS progression group
1.70(1.39–2.06)
MetS recovery group
1.87(1.48–2.36)
- Participants developed a multimorbidity
- 930
Observational data: associations, not effects.
Further findings
Proportion mediated by LE8 score
- MetS progress
- 24.1% (95% CI: 11.4-44.0)
- MetS recover
- 25.7% (95% CI: 16.4-37.7)
- Persistent MetS
- 19.5% (95% CI: 13.7-26.9)
- Survival mediation analysis
Original publication
Metabolic Syndrome Evolution and Cardio-Kidney-Metabolic Multimorbidity: Implications for Targeted Prevention. JACC Adv. Published 21 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →